Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Anaplastic lymphoma kinase (ALK) is a potential therapeutic target in neuroblastoma.
• Crizotinib, an ALK inhibitor, shows limited clinical benefit in ALK-positive neuroblastoma patients.
• The molecular mechanisms of aberrant ALK activity in neuroblastoma are not fully understood.

Purpose of the Study:

• To investigate the downstream signaling pathways regulated by aberrant ALK activity in neuroblastoma.
• To identify novel therapeutic targets by understanding the molecular mechanisms of ALK inhibition.

Main Methods:

• Deep quantitative phosphoproteomics was employed on Crizotinib-treated neuroblastoma cell lines.
• Bioinformatic analysis was used to identify significantly regulated phosphoproteins and signaling pathways.
• Functional experiments were conducted to validate the role of identified pathways in neuroblastoma growth.

Main Results:

• Over 10,000 phosphorylation sites were quantitatively analyzed, identifying 450-790 significantly regulated sites.
• The RAS/JNK pathway was identified as a downstream signaling pathway of ALK, irrespective of the ALK variant.
• Inhibition of ALK/JNK signaling led to neuroblastoma cell growth inhibition via cell cycle arrest and apoptosis.

Conclusions:

• The RAS/JNK pathway is a critical downstream mediator of ALK signaling in neuroblastoma.
• Targeting the ALK/JNK pathway presents a promising therapeutic strategy for neuroblastoma treatment.
• This study provides a comprehensive phosphoproteomic resource for further clinical investigation of ALK inhibitors in neuroblastoma.